Trial reportNeuro-oncology2018
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Frontiers in medicine · 2026Pooled it
- Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.Neuro-oncology · 2023Pooled it
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.Neuro-oncology · 2018Trial
- Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.International journal of molecular sciences · 2026Review
- Donafenib suppresses glioblastoma progression: potential enhancement of therapeutic response in TMZ-resistant models.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Efficacy of tepotinib in patients with high-grade glioma withNeuro-oncology practice · 2026Article
- Review
- Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets.Cancer metastasis reviews · 2026Review
- Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors.International journal of molecular sciences · 2026Review
- Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance.Current pharmaceutical design · 2026Review
- Immune Landscape and Application of Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2025Review
- Review
- Article
- Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion.The oncologist · 2025Article
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.Cancers · 2024Review
- MPZL1 as an HGF/MET signaling amplifier promotes cell migration and invasion in glioblastoma.Genes & diseases · 2024Article
- AberrantCells · 2024Review
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Jan DrappatzCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
John de GrootCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Michael D PradosCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
David A ReardonCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
David SchiffCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Marc ChamberlainCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Tom MikkelsenCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Annick DesjardinsCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Jaymes HollandCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Jerry PingCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Ron WeitzmanCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Timothy F CloughesyCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).
Exelixis (United States) · USDuke University · USCenter for Neuro-Oncology · USDana-Farber Brigham Cancer Center · USFred Hutch Cancer Center · USHenry Ford Health System · USRonald Reagan UCLA Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Virginia Health System · US
Funding
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MNCI NIH HHS P50 CA211015
Abstract
Background: Cabozantinib is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET that has demonstrated clinical activity in advanced solid tumors. This open-label, phase II trial evaluated cabozantinib in patients with recurrent or refractory glioblastoma (GBM). Methods: Patients were initially enrolled at a starting dose of 140 mg/day, but the starting dose was amended to 100 mg/day because of toxicity. Treatment continued until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed by an independent radiology facility using modified Response Assessment in Neuro-Oncology criteria. Additional endpoints included duration of response, 6-month and median progression-free survival, overall survival, and safety. Results: Among 152 patients naive to prior antiangiogenic therapy, the objective response rate was 17.6% and 14.5% in the 140 mg/day and 100 mg/day groups, respectively, which did not meet the predefined statistical target for success. The proportions of patients alive and progression free at 6 months were 22.3% and 27.8%, respectively. Median progression-free survival was 3.7 months in both groups, and median overall survival was 7.7 months and 10.4 months, respectively. The incidence of grade 3/4 adverse events (AEs) was 79.4% and 84.7% in the 140 mg/day and 100 mg/day groups, respectively, and dose reductions due to AEs were experienced by 61.8% and 72.0%, respectively. Common grade 3/4 AEs included fatigue, diarrhea, and palmar-plantar erythrodysesthesia syndrome. Conclusions: Cabozantinib showed evidence of clinical activity in patients with recurrent GBM naive to antiangiogenic therapy, although the predefined statistical target for success was not met. At the starting doses assessed, AEs were frequently managed with dose reductions. Clinical Trials Registration Number: NCT00704288 (https://www.clinicaltrials.gov/ct2/show/NCT00704288).
Indexed as
AdultAgedAngiogenesis InhibitorsAnilidesData AnalysisDisease-Free SurvivalFemaleGlioblastomaHumansKaplan-Meier EstimateMaleMiddle AgedProtein Kinase InhibitorsPyridinesTreatment OutcomeAngiogenesis InhibitorsAnilidescabozantinibProtein Kinase InhibitorsPyridinesantiangiogeniccabozantinibnaiveprogressive glioblastomarecurrent
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT00704288ClinicalTrials.gov
NCT05425004ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.